Pyxis Oncology, Inc. (PYXS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1/A
Revenues	0.0	86.1	0.0	51.1	0.0	1.2
Revenue growth		68.7%			-100.0%
Cost of goods sold	0.0	123.5	0.0	69.7	0.0	2.9
Gross profit	0.0	-37.4	0.0	-18.7	0.0	-1.7
Gross margin		-43.4%		-36.6%		-135.2%
Selling, general and administrative [+]	37.4	37.4	18.7	18.7	3.8	1.7
General and administrative	37.4	37.4	18.7	18.7	3.8	1.7
Research and development	86.1		51.1		9.0
Equity in earnings			-0.2
Other operating expenses		48.8		32.4		-0.4
EBITDA [+]	-122.8		-69.3		-12.4
EBITDA growth	77.2%	77.1%	457.8%		331.6%
EBITDA margin		-143.4%		-136.6%		-235.2%
Depreciation and amortization	0.7		0.6		0.5
EBIT [+]	-123.5	-123.5	-69.9	-69.7	-12.9	-2.9
EBIT growth	76.5%	77.1%	442.5%		347.9%
EBIT margin		-143.4%		-136.6%		-235.2%
Interest income	2.8		0.0		0.1	0.1
Interest income	2.8		0.0		0.1	0.1
Other income (expense), net [+]		123.5	-6.1	69.7		2.8
Gain (loss) on derivative instruments			-6.2
Unrealized gain/loss on derivatives				-6.2
Pre-tax income	-120.7	0.0	-76.0	0.0	-12.8	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%		0.0%		0.0%
Net income	-120.7	0.0	-76.0	0.0	-12.8	0.0
Net margin		0.0%		0.0%		0.0%

Basic EPS [+]	($3.65)	$0.00	($8.95)	$0.00	($12.45)	$0.00
Growth	-59.1%		-28.1%
Diluted EPS [+]	($3.65)	$0.00	($8.95)	$0.00	($12.45)	$0.00
Growth	-59.1%		-28.1%

Shares outstanding (basic) [+]	33.0	33,033.1	8.5	8,493.3	1.0	671.8
Growth	288.9%	288.9%	724.1%		-99.8%
Shares outstanding (diluted) [+]	33.0	33,033.1	8.5	8,493.3	1.0	671.8
Growth	288.9%	288.9%	724.1%		-99.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.